Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney disease

Journal of Clinical Pharmacology

Volumn 48, Issue 7, 2008, Pages 837-848

  Knebel, William ^a,c   Palmen, Mary ^b   Dowell, James A ^b   Gastonguay, Marc ^a  

^a Metrum Research Group LLC   (United States)

^b Shire Pharmaceuticals   (United Kingdom)

^c NONE   (United States)

Author keywords

Chronic kidney disease; Epoetin delta; Erythropoietin; Pediatrics; Population pharmacokinetic modeling

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADOLESCENT; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; MULTICENTER STUDY; PHARMACOKINETICS; PHASE 3 CLINICAL TRIAL; POPULATION PHARMACOKINETICS; POPULATION RESEARCH; PRESCHOOL CHILD; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT DURATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; INFANT; KIDNEY DISEASES; MALE; MODELS, BIOLOGICAL;

EID: 45749126082     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008318218     Document Type: Article

References (29)

1. Brandt JR, Avner ED, Hickman RO, Watkins SL Safety and efficacy of erythropoietin in children with chronic renal failure. Pediatr Nephrol. 1999 ; 13: 143-147.
2. Sieniawska M., Roszkowska-Blaim M. Recombinant human erythropoietin dosage in children undergoing hemodialysis and continuous ambulatory peritoneal dialysis. Pediatr Nephrol. 1997 ; 11: 628-630.
3. Jabs K., Harmon WE Recombinant human erythropoietin therapy in children on dialysis. Adv Ren Replace Ther. 1996 ; 3: 24-36.
4. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am. 1987 ; 34: 571-590.
5. Yalcinkaya F., Tumer N., Cakar N., Ozkaya N. Low-dose erythropoietin is effective and safe in children on continuous ambulatory peritoneal dialysis. Pediatr Nephrol. 1997 ; 11: 350-352.
6. Ongkingco JR, Ruley EJ, Turner ME, Fragale MR Efficacy of once- versus thrice-weekly subcutaneous recombinant human erythropoietin in children receiving continuous cycling peritoneal dialysis. Am J Nephrol. 1994 ; 14: 14-18.
7. Jacobs K., Shoemaker C., Rudersdorf R., et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature. 1985 ; 313: 806-810.
8. Lin FK, Suggs S., Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA. 1985 ; 82: 7580-7584.
9. Shahrokh Z., Flatman M., Davies M. Erythropoietin produced by a human cell line has only trace levels of potentially immunogenic N-glycolylneuraminic acid residues [abstract]. Haematologica. 2006 ; 91 (suppl 1). 208.
10. Elliott S., Egrie J., Browne J., et al. Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol. 2004 ; 32: 9.
11. McVicar C., Gardiner T., Stitt A. Human cell-derived epoetin delta is less angiogenic than darbepoetin alfa in vitro. Presented at: American Society of Nephrology Renal Week ; November 2-5, 2007 ; San Francisco, California.
12. Kwan JT, Pratt RD Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients. Curr Med Res Opin. 2007 ; 23: 307-311.
13. Martin KJ The first human cell line-derived erythropoietin, epoetin-delta (Dynepo), in the management of anemia in patients with chronic kidney disease. Clin Nephrol. 2007 ; 68: 26-31.
14. Spinowitz BS, Pratt RD Epoetin delta is effective for the management of anaemia associated with chronic kidney disease. Curr Med Res Opin. 2006 ; 22: 2507-2513.
15. Smith WB, Dowell JA, Pratt RD Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease. Clin Ther. 2007 ; 29: 12.
16. Validation of a Manual Method to Quantify Erythropoietin in Human Serum by an Enzyme Linked Immunosorbent Assay. Bioanalytical Method Report HMR4396-P3A. Kansas City, MO: Quintiles, Inc; 2007.
17. NMQual: NONMEM installation utility. Augusta, ME: Metrum Institute ; 2007. Available at: http://metruminstitute.org.
18. Harrell FE Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer-Verlag ; 2001.
19. Ette EI, Ludden TM Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res. 1995 ; 12: 1845-1855.
20. Holford NH A size standard for pharmacokinetics. Clin Pharmacokinet. 1996 ; 30: 329-332.
21. Yano Y., Beal SL, Sheiner LB Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check. J Pharmacokinet Biopharm. 2001 ; 28: 171-192.
22. Parke J., Holford NH, Charles BG A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed. 1999 ; 59: 19-29.
23. Ette EI, Onyiah LC Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with Winsorization. Eur J Drug Metab Pharmacokinet. 2002 ; 27: 213-224.
24. Efron B. Missing data, imputation, and the bootstrap. J Am Stat Assoc. 1994 ; 89: 463-479.
25. Ette EI Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997 ; 37: 486-495.
26. Ramakrishnan R., Cheung WK, Wacholtz MC, Minton N., Jusko WJ Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol. 2004 ; 44: 991-1002.
27. Krzyzanski W., Jusko WJ, Wacholtz MC, Minton N., Cheung WK Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci. 2005 ; 26: 295-306.
28. Olsson-Gisleskog P., Jacqmin P., Perez-Ruixo JJ Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects. Clin Pharmacokinet. 2007 ; 46: 159-173.
29. Mahmood I. Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol. 2006 ; 61: 545-557.